Solid Phase Peptide Synthesis: Cycle, Yield Math, Quality Checks

Solid phase peptide synthesis anchors the first amino acid's carboxyl end (the C-terminus) to an insoluble resin and adds protected amino acids one at a time toward the amino end (the N-terminus). Each cycle deprotects, washes, couples and washes again. Excess reagents leave by filtration because the chain stays on the resin. Merrifield's work earned the 1984 Nobel Prize in Chemistry.

One cycle in the Fmoc strategy runs like this:

Fmoc is the most commonly used alpha-amine protecting group in SPPS, per the same primer. The older Boc (tert-butyloxycarbonyl) strategy removes its protecting group with acid and needs harsher final cleavage. It remains in use for some sequences, notably those prone to aggregation.

Solution-phase synthesis, where every intermediate is isolated, still has a place for short peptides and for making fragments. Solid phase wins for most sequences because washing replaces isolating.

Because full-length yield is the per-cycle efficiency multiplied by itself once for every coupling, so small losses compound. A peptide of n residues needs n−1 couplings when the first residue is preloaded on the resin. The fraction of fully correct chains is efficiency raised to the power n−1.

At 99% per cycle, a 31-residue backbone (the length of semaglutide's) gives only about 74% full-length chains. Our model, assuming every cycle has the same independent efficiency, gives these full-length percentages:

Working backward, the per-cycle efficiency needed for 70% full-length chains is 0.70 raised to the power 1/(n−1):

• 20 residues: 98.14%
• 31 residues: 98.82%
• 39 residues: 99.07%
• 50 residues: 99.27%

This is our model, not a measured result. Real efficiency varies by sequence, with hydrophobic stretches and bulky residues being the usual trouble spots, and a real 99% cycle is an average of easy and hard couplings. The model also covers crude material only. Purification costs further yield: for a standard Fmoc peptide at bench scale, the American Peptide Society primer puts typical yield after purification at approximately 30–40%.

Our inference, not a regulatory limit: past roughly 40 to 50 residues, a single linear run becomes hard to keep clean, because the model above falls below 62% full-length at 99% per cycle. The same logic favors fragments. Lilly's published kilogram-scale good manufacturing practice (GMP) route to tirzepatide, a 39-residue peptide, combines solid phase and liquid-phase steps, per Organic Process Research & Development. A buyer should ask which route a supplier uses.

Each SPPS failure leaves a different impurity and needs a different test: mass spectrometry catches missing or extra residues, while same-mass stereoisomers need a dedicated method. As of October 2026, the adopted EMA guideline (EMA/CHMP/CVMP/QWP/367182/2025, adopted December 2025) has applied since 1 June 2026. It sorts impurities in the way the table below does.

Two terms first. Liquid chromatography-mass spectrometry (LC-MS) separates a sample on a column and then weighs each component. A chromatogram is the chart that shows each compound as a peak.

The guideline's reasoning behind the rows:

• Deletions come from incomplete coupling or deprotection. They are often prevented by repeating the coupling and capping unreacted sites, which produces truncated sequences.
• Insertions arise from free amino acid in the protected amino acid, premature deprotection during prolonged coupling, or incomplete removal of excess amino acid before the next deprotection.
• Urethane-protected amino acids such as Fmoc derivatives resist the pathway that causes epimerization.
• Impurities are judged against the European Pharmacopoeia (Ph. Eur.) general monograph for pharmaceutical substances: reported above 0.1%, identified above 0.5%, qualified above 1.0%.
• If co-eluting impurities appear as one peak, the 1.0% qualification threshold applies unless justified otherwise. That is exactly how deletion sequences hide.

For in-process control, the guideline names the Kaiser test as the most common check on coupling, capping and deprotection, with the chloranil and TNBS tests as equivalents. The Kaiser test is a colorimetric reaction of ninhydrin with primary amines: blue means free amine remains, so couple again. Proline's secondary amine gives only a weak red-brown result.

This is an EU document. For a US filing, the expectations come from the U.S. Food and Drug Administration (FDA), so use these thresholds as working pass marks rather than US limits.

Three distinctions prevent most misreadings:

• Purity is not yield. A pure peptide can still have been recovered at low yield.
• Purity is not content. HPLC area percent says nothing about water or counter-ion weight. Our page on peptide HPLC purity versus content explains the difference.
• Correct mass is not correct identity. Different sequences or stereoisomers can share a mass.

For general API testing methods (HPLC, infrared, mass spectrometry), see our pharmaceutical API quality testing guide.

Ask five things: the synthesis route, the residue count, the in-process controls, the identified impurity table, and the identity tests beyond mass. A supplier who can answer all five has shown control of the process. One who offers only a purity percentage has not. Our guide on how to qualify a peptide contract development and manufacturing organization (CDMO) extends these questions to audits and documentation.

Run these as pass or fail checks:

As of October 2026, FDA Import Alert 66-80 allows FDA to detain GLP-1 receptor agonist APIs, including semaglutide and tirzepatide, without physical examination, unless they come from manufacturers on FDA's Green List. The alert cites 21% of the 48 API manufacturing sites FDA evaluated as noncompliant under section 501 of the Federal Food, Drug, and Cosmetic Act.

For a US buyer the practical test is the site, not the supplier's name. Ask any supplier, including us, which manufacturing site made the lot and whether that site is on the Green List. Pass: a named site, confirmed against FDA's list. Fail: no site named. Manufacturers seek Green List entry by submitting documentation, including certificates of analysis for recent lots, to FDA.

We supply peptide APIs as bulk raw powder for business buyers, not as finished lyophilized vials. Our peptide portfolio includes semaglutide, tirzepatide and liraglutide, among other peptide raw materials, and we support small clinical peptide batches of 5 grams.

Regulatory status is set molecule by molecule, and the regulator's record is the reference. FDA has approved finished drugs containing semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Victoza). Our inference: those approvals cover specific finished products and say nothing about any particular API source, so each lot still needs its own documentation. We do not represent research-only or evaluation-only materials as approved human pharmaceutical APIs. You are responsible for confirming local registration, import authorization and permitted end use before commercial supply.

We confirm the synthesis route and source, minimum order quantity and lead time product by product at quotation, because they depend on the approved manufacturing source and current availability. Documentation may include a COA, specifications and a safety data sheet (SDS) where applicable. Prices are quoted per product on request. As of October 2026, payment for international commercial orders is generally 100% advance by bank transfer unless otherwise agreed in writing.

To request a quotation, send the product name or Chemical Abstracts Service (CAS) registry number, quantity, destination, grade or purity, documents needed, payment terms and Incoterms (International Commercial Terms, the delivery and risk rules for shipping) through our contact page, to sunil@aarisepharma.com, or by WhatsApp at +91 9899783330.